Eli Lilly CEO: Medicare GLP-1 Coverage Adds 700,000 New Senior Users
Eli Lilly reports 700,000 seniors began GLP-1 therapy after Medicare coverage launched in July, with 70% choosing Lilly drugs.
Some 700,000 Medicare-eligible seniors have started GLP-1 medications since federal coverage for the drug class took effect in July, Eli Lilly's chief executive disclosed, offering the clearest picture yet of how broadly the policy change is reshaping access to the blockbuster weight-loss and diabetes treatments.
Of those newly covered patients, roughly 70 percent are taking a Lilly product, the CEO said, underscoring the Indianapolis-based drugmaker's commanding position in a market it shares primarily with Danish rival Novo Nordisk. The figures signal that Medicare's decision to cover GLP-1s is translating quickly into real-world prescriptions rather than sitting as an unrealized benefit.
Read more Jersey Mike's Eyes Younger Customers After Sub Market Gains →
The data points carry weight beyond a single company's earnings narrative. Analysts have watched Medicare GLP-1 coverage closely as a test of whether government insurance can meaningfully broaden access to drugs that carry list prices in the hundreds of dollars per month, a barrier that historically kept them out of reach for many older Americans on fixed incomes.
Lilly's share of the new cohort also reflects the competitive dynamics of a category where both Ozempic-maker Novo Nordisk and Lilly's Mounjaro and Zepbound franchises are locked in an accelerating race for market share. A 70 percent capture rate among first-time Medicare users would represent a significant early-adoption advantage if it holds as enrollment grows.
Continue reading at US Top News and Analysis.
